Biofrontera (BFRI) Projected to Post Quarterly Earnings on Thursday

Biofrontera (NASDAQ:BFRI) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.1150) per share and revenue of $10.25 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 11:00 AM ET.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.21. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $16.15 million. On average, analysts expect Biofrontera to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biofrontera Stock Performance

Biofrontera stock opened at $1.01 on Wednesday. Biofrontera has a 12-month low of $0.54 and a 12-month high of $1.19. The company has a market capitalization of $12.13 million, a price-to-earnings ratio of -0.98 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.52 and a quick ratio of 1.40. The firm’s fifty day moving average price is $0.97 and its 200 day moving average price is $0.90.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biofrontera currently has a consensus rating of “Hold” and an average target price of $2.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. grew its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the period. Biofrontera comprises approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th biggest position. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.